PDS Biotechnology Corporation [NASDAQ: PDSB] closed the trading session at $5.27 on 03/11/21. The day’s price range saw the stock hit a low of $4.52, while the highest price level was $7.07. The company report on March 11, 2021 that PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million.
Development and commercialization of novel T-cell activating vaccine to be performed in Brazil by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary Versamune® T-cell activating technology, announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.
The stocks have a year to date performance of 146.26 percent and weekly performance of 56.38 percent. The stock has been moved at 141.74 percent over the last six months. The stock has performed -22.61 percent around the most recent 30 days and changed 116.87 percent over the most recent 3-months.
If compared to the average trading volume of 873.15K shares, PDSB reached to a volume of 45718825 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PDS Biotechnology Corporation [PDSB]:
H.C. Wainwright have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on May 27, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $5.45, while Noble Capital Markets analysts kept a Outperform rating on PDSB stock.
The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.83 The Price to Book ratio for the last quarter was 3.21, with the Price to Cash per share for the same quarter was set at 1.55.
PDSB stock trade performance evaluation
PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 56.38. With this latest performance, PDSB shares dropped by -22.61% in over the last four-week period, additionally plugging by 141.74% over the last 6 months – not to mention a rise of 472.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 61.13, with the RSI for the last a single of trading hit 65.36, and the three-weeks RSI is set at 59.74 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 3.68, while it was recorded at 4.03 for the last single week of trading, and 2.67 for the last 200 days.
PDS Biotechnology Corporation [PDSB]: An insightful look at the core fundamentals
Return on Total Capital for PDSB is now -74.68, given the latest momentum, and Return on Invested Capital for the company is -33.70. Return on Equity for this stock declined to -33.70, with Return on Assets sitting at -27.60.
Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$349,930 per employee.PDS Biotechnology Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.70 and a Current Ratio set at 11.70.
Earnings per share (EPS) analysis for PDS Biotechnology Corporation [PDSB] stock
With the latest financial reports released by the company, PDS Biotechnology Corporation posted -0.84/share EPS, while the average EPS was predicted by analysts to be reported at -0.92/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 8.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.
PDS Biotechnology Corporation [PDSB]: Insider Ownership positions
There are presently around $17 million, or 14.10% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 828,721, which is approximately 5.723% of the company’s market cap and around 27.61% of the total institutional ownership; VANGUARD GROUP INC, holding 714,037 shares of the stock with an approximate value of $2.71 million in PDSB stocks shares; and FEDERATED HERMES, INC., currently with $1.46 million in PDSB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 15 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 343,573 shares. Additionally, 9 investors decreased positions by around 493,305 shares, while 12 investors held positions by with 2,308,437 shares. The mentioned changes placed institutional holdings at 3,145,315 shares, according to the latest SEC report filing. PDSB stock had 7 new institutional investments in for a total of 114,932 shares, while 7 institutional investors sold positions of 472,250 shares during the same period.